Pharma Two B develops clinically differentiated and value-added products, based on approved drugs. The company focuses on Fixed-Dose-combinations of two or more drugs with complementary and synergistic effects, providing high clinical value and shorter regulatory pathways (US 505(b)(2) approach). The company develops products in two therapeutic areas with great unmet needs, Parkinson’s disease and Cancer.
The Company’s leading product, P2B001 was successfully tested in a phase IIb clinical study with 149 parkinson’s disease patients in the US and Israel. The results showed a significant effect of improvement in the subjects condition according to several Parkinson’s disease scales compared to Placebo.
Pharma Two B main investors include Crossroad and JK&B.
www.pharma2b.com
The Company’s leading product, P2B001 was successfully tested in a phase IIb clinical study with 149 parkinson’s disease patients in the US and Israel. The results showed a significant effect of improvement in the subjects condition according to several Parkinson’s disease scales compared to Placebo.
Pharma Two B main investors include Crossroad and JK&B.
www.pharma2b.com
Location: Israel, Center District, Rehovot
Employees: 11-50
Total raised: $38M
Founded date: 2007
Investors 4
| Date | Name | Website |
| - | Crossroad | crossroad-... |
| - | aMoon Fund | amoon.fund... |
| - | Israel Bio... | ibf.fund |
| - | JVC Invest... | jvcmanagem... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 27.02.2017 | - | $30M | - |
| 22.10.2012 | - | $8M | - |
Mentions in press and media 9
| Date | Title | Description |
| 19.05.2025 | OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals | OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Phar... |
| 04.09.2024 | Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger | KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) — Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson’s... |
| 15.12.2021 | Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease | REHOVOT, Israel, Dec. 15, 2021 /PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved drugs for neurological indications, today announced... |
| 27.02.2017 | Pharma Two B Ltd. Closes $30 Million Financing Round | - |
| 27.02.2017 | Pharma Two B Completes $30M Third Financing Round | Pharma Two B Ltd., a Rehovoth, Israel-based biopharmaceutical company focused on developing treatments for Parkinson’s disease, completed a $30m third round of financing. The round was led by Israel Biotech Fund (IBF) with participation fro... |
| 27.02.2017 | Term Sheet — Monday, February 27 | MONEYBALL FOR STARTUPS Crowdfunding watch: Is it fair to say the realities of equity crowdfunding have not lived up to the category’s promises? Most action in this once-hyped market has been limited to helping same institutional investors a... |
| 27.02.2017 | Pharma Two B raises $30M for Parkinson's phase 3 from Biogen-backed fund, adds ex-Pfizer CEO to board | Pharma Two B has raised $30 million (€28 million) to complete a phase 3 trial of its Parkinson’s asset P2B001. The round provides a hint of the impact of the recently founded Israel Biotech Fund (IBF), which led the investment and is adding... |
| 23.10.2012 | Pharma Two B Raises $8M in Second Round | REHOVOTH, ISRAEL, Privately held company focused on developing Fixed-Dose-Combinations (FDCs) of two or more drugs, completed its second round of financing and has raised $8 million. >> Click here for more funding data on Pharma Tw... |
| 22.10.2012 | Pharma Two B Completes $8M Second Financing Round | Pharma Two B Ltd., a Rehovoth, Israel-based company that focuses on developing Fixed-Dose-Combinations (FDCs) of two or more drugs with complementary and synergistic effects, has completed its $8m second round of financing. Backers include ... |